Drugs / navafenterol
navafenterol
English name Navafenterol
Small molecule targets ADRB2, CHRM3 via activation / inhibition
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT03159442 | Jun → Oct 2017 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02814656 | Jun → Nov 2016 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02573155 | Oct 2015 → Aug 2016 | asthma, chronic obstructive pulmonary disease | AstraZeneca | Completed | Met primary |
| Phase 22 trials · 2 met primary | ||||||
| Phase 2 | NCT03645434 | Oct 2018 → Aug 2019 | chronic obstructive pulmonary disease | AstraZeneca | Completed | Met primary |
| Phase 2 | NCT02971293 | Dec 2016 → Aug 2017 | chronic obstructive pulmonary disease | AstraZeneca | Completed | Met primary |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Navafenterol | “Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator” PMID 32907575 ↗ Sep 20202“Navafenterol (AZD8871) belongs to a new class of bronchodilator, the single-molecule muscarinic antagonist and β-agonist, developed for the treatment of COPD.” PMID 34503985 ↗ Apr 2022 “Navafenterol (AZD8871) in patients with mild asthma” PMID 32907576 ↗ Sep 2020 |
| Known as | AZD8871 | “Navafenterol (AZD8871) belongs to a new class of bronchodilator, the single-molecule muscarinic antagonist and β-agonist, developed for the treatment of COPD.” PMID 34503985 ↗ Apr 20224“Navafenterol (AZD8871) in patients with mild asthma” PMID 32907576 ↗ Sep 2020 |
| Known as | LAS-191351 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297483 ↗ |
| Action | Activate | “Beta-2 adrenergic receptor agonist” CHEMBL4297483 ↗ |
| Action | Inhibit | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL4297483 ↗ |
| Modality | Small molecule | “AZD8871 is a new chemical entity” NCT02814656 ↗ |
| Route | Inhaled | “administered via single-dose dry powder inhaler (Genuair®)” NCT02573155 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor agonist” CHEMBL4297483 ↗ |
| Target | CHRM3 | “Muscarinic acetylcholine receptor M3 antagonist” CHEMBL4297483 ↗ |